Unknown

Dataset Information

0

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer Patients.


ABSTRACT: Adjuvant bisphosphonate therapy is increasingly used in postmenopausal breast cancer patients. This is based on level-one evidence that bisphosphonates, particularly zoledronic acid, can effectively prevent cancer treatment-induced bone loss in breast cancer patients receiving estradiol-lowering endocrine therapies such as aromatase inhibitors. Furthermore, emerging data from large clinical trials suggest that additional anticancer benefits can be derived due to a positive impact on the bone marrow microenvironment.

PROVIDER: S-EPMC3132953 | BioStudies | 2010-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC4398333 | BioStudies
2013-01-01 | S-EPMC4723356 | BioStudies
| S-EPMC4295226 | BioStudies
| S-EPMC5605902 | BioStudies
| S-EPMC8718110 | BioStudies
| S-EPMC7357327 | BioStudies
| S-EPMC8166716 | BioStudies
| S-EPMC5541900 | BioStudies
| S-EPMC5519590 | BioStudies
| S-EPMC6533425 | BioStudies